long2017: Relapse-free survival of melanoma patients under adjuvant...

long2017R Documentation

Relapse-free survival of melanoma patients under adjuvant treatment

Description

Data stem from a double-blind, placebo-controlled phase 3 trial where n=870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations were randomly assigned to receive oral Dabrafenib plus Trametinib (combination therapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months.

Usage

long2017

Format

A data frame with 870 rows and 4 variables:

ID

artificially generated patient ID

time

Time to relapse-free survival in months

status

Status of observation, encoded as 0 for right-censoring vs 1 for RFS-event

trtmt

Treatment group: Dabrafenib+Trametinib vs Placebo

Details

Unfortunately, the data set of the clinical trial is not publicly available. Instead, the data were digitized by Sean Devlin based on the published survival plot (see Fig 1A in the original publication of the trial results). Therefore, the data given here do not claim to be a 100% faithful representation of the clinical trial. Some deviations are to be expected.

Source

Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377(19):1813-1823. doi:10.1056/NEJMoa1708539

Devlin SM and O'Quigley J, The nph2ph-transform: applications to the statistical analysis of completed clinical trials, arXiv:2407.18905, 2024. doi:10.48550/arXiv.2407.18905.


incubate documentation built on Nov. 22, 2026, 1:07 a.m.